Ageless Pep Academy Clinical Education · Licensed Prescribers

Teriparatide

Teriparatide

⚠️ Structural Separation Notice

The Ageless Pep Academy is a clinical education property independent from any commerce operation. Any references in this profile to Ageless Peps product SKUs, pricing, or the agelesspeps.com domain are for completeness and transparency; they are not endorsements and do not form part of the clinical education content. Clinicians are responsible for independent verification of any product sourcing decision. The Academy's Medical Director provides editorial oversight only and does not endorse commercial products.

Recombinant PTH(1-34) fragment; the first FDA-approved anabolic agent for osteoporosis that stimulates new bone formation via intermittent parathyroid hormone receptor activation.

Quick Facts

Property Value
Also Known As Forteo, PTH(1-34), recombinant parathyroid hormone fragment, LY333334
Category Bone / Endocrine
Sequence H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH
Molecular Weight ~4117 Da
Molecular Formula C181H291N55O51S2
PubChem CID 16133828
Administration SubQ (thigh, abdomen)
Typical Dose Range 20 mcg once daily (FDA-approved dose)
Half-Life ~1 hour (SubQ injection)
Storage Refrigerated (2-8C); discard after 28 days of first use; do not freeze
FDA Status Approved (2002) — Forteo for osteoporosis in postmenopausal women and men at high fracture risk; glucocorticoid-induced osteoporosis
WADA Status Not prohibited (FDA-approved medication)

Mechanism of Action

Teriparatide is the bioactive N-terminal 34-amino-acid fragment of human parathyroid hormone (PTH). It exerts its effects by binding to the parathyroid hormone 1 receptor (PTH1R), a G protein-coupled receptor (GPCR) expressed on osteoblasts, osteocytes, and renal tubular cells. The critical pharmacological principle underlying teriparatide is the anabolic window: intermittent (pulsatile) PTH1R activation preferentially stimulates osteoblast-mediated bone formation, while continuous PTH exposure favors osteoclast-mediated bone resorption.

When teriparatide is injected once daily, serum PTH(1-34) levels rise rapidly, peak at ~30 minutes, and return to baseline within 3-4 hours. This brief pulse activates osteoblast signaling pathways including Wnt/beta-catenin, Runx2 transcription factor upregulation, and suppression of sclerostin (the endogenous Wnt pathway inhibitor produced by osteocytes). The net effect during the first 6-12 months of therapy is a period of predominant bone formation over resorption — the "anabolic window" — during which BMD increases substantially (PMID: 11346808).

Over longer treatment (12-24 months), osteoclast activity gradually catches up as bone remodeling is coupled, and the anabolic window narrows. This is one reason teriparatide treatment is limited to 24 months. After discontinuation, the gains in BMD and bone architecture are progressively lost unless an antiresorptive agent (bisphosphonate or denosumab) is initiated, establishing the sequential therapy paradigm: build bone first with teriparatide, then lock it in with an antiresorptive (PMID: 30694878).

In the kidney, PTH1R activation increases calcium reabsorption and phosphate excretion, and stimulates 1,25-dihydroxyvitamin D production. Mild transient hypercalcemia (typically <11 mg/dL) is the most common metabolic effect.

Key Research Areas

  1. Vertebral fracture prevention — The landmark Neer 2001 trial (n=1637) demonstrated a 65% reduction in new vertebral fractures with 20 mcg/day teriparatide vs placebo over median 21 months (PMID: 11346808)
  2. Non-vertebral fracture reduction — 53% reduction in non-vertebral fragility fractures in the pivotal trial; subsequent meta-analyses confirm a consistent 40-56% reduction (PMID: 39222329)
  3. Superiority over bisphosphonates — Meta-analysis of 23 RCTs shows teriparatide produces greater BMD gains at lumbar spine and femoral neck vs bisphosphonates and denosumab (PMID: 39222329)
  4. Glucocorticoid-induced osteoporosis — Superior to alendronate in preventing vertebral fractures in patients receiving chronic glucocorticoids
  5. Sequential therapy — Teriparatide followed by antiresorptive therapy maintains or extends BMD gains; antiresorptive-first then teriparatide may blunt the anabolic response (PMID: 30694878)
  6. Fracture healing acceleration — Emerging evidence for off-label use in accelerating healing of difficult fractures (non-unions, stress fractures)

Evidence Level Summary

Evidence Type Count Notes
Systematic reviews 2 Comprehensive fracture prevention reviews
Human RCTs 1 Pivotal Neer 2001 Fracture Prevention Trial (n=1637)
Human observational 0 —
Animal in vivo 0 —
In vitro 0 —

Clinical Applications

  • Osteoporosis — Primary indication: postmenopausal women and men at high fracture risk, glucocorticoid-induced osteoporosis
  • Fracture healing — Off-label use for delayed unions and non-unions

Protocols Using This Peptide

  • No current vault protocols use teriparatide (FDA-approved prescription medication, not a research peptide)

Ageless Peps Products

  • APWS-Teriparatide-Vial — Teriparatide 10mg Vial, $74, wholesale only (clinical label)

Dosing Reference

FDA-Approved Dosing

Indication Dose Route Frequency Duration Source
Osteoporosis (postmenopausal women) 20 mcg SubQ Once daily Up to 24 months FDA label
Osteoporosis (men at high fracture risk) 20 mcg SubQ Once daily Up to 24 months FDA label
Glucocorticoid-induced osteoporosis 20 mcg SubQ Once daily Up to 24 months FDA label

Cycling

Teriparatide is limited to 24 months of continuous use based on the FDA label. This restriction originated from rodent toxicology studies showing osteosarcoma in Fischer 344 rats at high doses and long durations. The 24-month limit remains precautionary; no increased osteosarcoma risk has been observed in humans after >15 years of post-marketing surveillance. After completing teriparatide, patients transition to an antiresorptive (bisphosphonate or denosumab) to maintain BMD gains. Repeat courses of teriparatide have been studied but are not routinely recommended.

Contraindications & Safety

  • Contraindications: Hypercalcemia, metabolic bone disease other than osteoporosis (e.g., Paget's disease), unexplained elevated alkaline phosphatase, prior radiation to bone, open epiphyses (children/adolescents), pre-existing hypercalcemia, severe renal impairment
  • Black box warning (historical): Osteosarcoma risk — based on rodent studies only; human post-marketing surveillance has not confirmed this risk. The black box was removed from the US label in 2020 based on 15+ years of safety data.
  • Common side effects: Nausea, dizziness, leg cramps, orthostatic hypotension, transient hypercalcemia, injection site reactions
  • Drug interactions: Digitalis (hypercalcemia may potentiate digitalis toxicity); concurrent use with bisphosphonates may blunt anabolic response (sequential use preferred)
  • Pregnancy/nursing: Contraindicated (Category C)
  • Special populations: Not studied in pediatric patients; no dose adjustment needed for mild-moderate renal impairment; contraindicated in severe renal impairment

Synergistic Combinations

  • Denosumab (sequential after teriparatide) — Consolidates BMD gains from anabolic phase
  • Vitamin D + Calcium — Essential co-supplementation during teriparatide therapy
  • Note: Concurrent bisphosphonate use is NOT recommended as it may blunt the anabolic response

Related Research

PMID Title Year Study Type
11346808 Effect of PTH(1-34) on Fractures and BMD in Postmenopausal Women 2001 RCT
30694878 Clinical Application of Teriparatide in Fracture Prevention: A Systematic Review 2019 Systematic Review
39222329 Teriparatide in Postmenopausal Osteoporosis: Meta-Analysis vs Other Treatments 2024 Meta-analysis

References

Related

#peptide #fda-approved #not-sold #subq